LivaNovaLIVN +1.40%76 Net Margin % is 6.16% as of Mar. 2026. GuruFocus rates LIVN with a GF Score™ of 76/100 and a GF Value™ of $62.48 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 817 Medical Devices & Instruments companies, LivaNova ranks better than 66.1% on this metric.
Net margin is calculated as Net Income divided by its Revenue. LivaNova's Net Income for the
three
months ended in Mar. 2026 was $22 Mil. LivaNova's Revenue for the
three
months ended in Mar. 2026 was $362 Mil. Therefore, LivaNova's net margin for the quarter that ended in Mar. 2026 was 6.16%.
The historical rank and industry rank for LivaNova's Net Margin % or its related term are showing as below:
LIVN'
s Net Margin % Range Over the Past 10 Years
Min: -37.34 Med: -10.78 Max: 7.48
Current: 7.48
LIVN's Net Margin % is ranked better than 66.1% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs LIVN: 7.48
LivaNova (NAS:LIVN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
LivaNova Net Margin % Related Terms
LivaNova Net Margin % Historical Data
* Premium members only.
The historical data trend for LivaNova's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LivaNova's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Net Margin % distribution charts can be found below:
* The bar in red indicates where LivaNova's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LivaNova (LIVN) has a Net Margin % of 6.16% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on LivaNova and its competitors. According to the industry distribution chart, LivaNova ranks #277 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is LivaNova's Net Margin % too high?
LivaNova's current Net Margin % is 6.16%. The Medical Devices & Instruments industry median Net Margin % is 2.07. LivaNova's value of 6.16% is 197.6% above this industry median. Based on the distribution chart, LivaNova ranks #277 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LivaNova has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's Net Margin % compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #277 out of 817 companies for Net Margin %. This puts LivaNova in the upper half of its industry. The industry median Net Margin % is 2.07. LivaNova's value of 6.16% is 197.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LivaNova's current Net Margin % of 6.16% is 197.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on LivaNova and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LivaNova's current Net Margin % is 6.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Modestly Overvalued. The stock's GF Value™ is $62.48, compared to a current price of $81.05 — trading 29.7% above its estimated fair value. The current Net Margin % is 6.16% and 197.6% above the Medical Devices & Instruments industry median of 2.07. LivaNova's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For LivaNova (LIVN), the current Net Margin % is 6.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LivaNova (LIVN) Overvalued in 2026?
Based on GuruFocus' analysis, LivaNova stock appears to be overvalued.
The current stock price of $81.05 is trading 29.7% above its estimated GF Value™ of $62.48.
GuruFocus considers LivaNova to be Modestly Overvalued.
Key valuation signals for LIVN:
Net Margin %: 6.16%
GF Value™: $62.48 vs. price of $81.05 (29.7% above fair value)
Industry Position: 197.6% above the Medical Devices & Instruments median (#277 of 817)
No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
76GF Score
Get the complete analysis for LIVN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIVN has been successfully added to your 
